Trial Profile
Phase 4- The role of montelukast on perennial rhinitis and associated sleep disturbance and daytime somnolence
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- 04 Nov 2008 Secondary endpoint 'Symptom score' has been met.
- 01 Apr 2008 Primary endpoint 'Epworth Sleepiness Scale' has been met.
- 01 Apr 2008 Secondary endpoint 'Rhinoconjunctivitis Quality of Life Questionnaire' has been met.